These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 10905396

  • 1. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    J Pediatr Endocrinol Metab; 2000 Jun; 13(6):677-80. PubMed ID: 10905396
    [Abstract] [Full Text] [Related]

  • 2. Chelation therapy and bone metabolism markers in thalassemia major.
    Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, De Sanctis V.
    J Pediatr Endocrinol Metab; 2006 Nov; 19(11):1335-42. PubMed ID: 17220062
    [Abstract] [Full Text] [Related]

  • 3. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R.
    Blood; 2006 May 01; 107(9):3738-44. PubMed ID: 16352815
    [Abstract] [Full Text] [Related]

  • 4. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A.
    Blood; 2006 May 01; 107(9):3733-7. PubMed ID: 16373663
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 01; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 7. Development of oral iron chelator L1.
    Hershko C.
    Lancet; 1993 Apr 24; 341(8852):1088-9. PubMed ID: 8096975
    [No Abstract] [Full Text] [Related]

  • 8. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Apr 24; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 9. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Apr 24; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 10. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    Minerva Pediatr; 2000 Apr 24; 52(4):235-41. PubMed ID: 11995208
    [Abstract] [Full Text] [Related]

  • 11. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 24; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 14. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.
    Mutagenesis; 2003 Sep 11; 18(5):457-63. PubMed ID: 12960415
    [Abstract] [Full Text] [Related]

  • 15. Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
    Pradhan V, Badakere S, Ghosh K.
    Acta Haematol; 2003 Sep 11; 109(1):35-9. PubMed ID: 12486321
    [Abstract] [Full Text] [Related]

  • 16. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 17. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 18; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 19. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.